Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with a focus on neuroscience and intranasal pherine product candidates. The VTGN news feed highlights the company’s progress as it advances its nose-to-brain neurocircuitry platform for conditions such as social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) due to menopause.
News about Vistagen frequently covers clinical trial milestones, including updates from its PALISADE Phase 3 public speaking challenge studies of fasedienol for the acute treatment of social anxiety disorder. These items may include announcements that randomized, double-blind, placebo-controlled trial phases have been completed, topline results from specific studies such as PALISADE-3, and commentary on how outcomes compare with earlier trials like PALISADE-2. The company also reports on exploratory and nonclinical data for other pherine candidates, such as PH80 for menopausal hot flashes, including findings on brain and autonomic effects and mechanistic insights presented at scientific meetings.
Investors and observers can also find corporate and governance updates in Vistagen’s news, such as board appointments, executive leadership changes, and participation in healthcare and neuropsychiatry conferences. Press releases may discuss new director appointments, additions to the executive team, and information about investor presentations and conference webcasts.
For those tracking VTGN, the news stream offers a consolidated view of clinical, scientific, and corporate developments that shape the company’s pherine pipeline and regulatory strategy. Regularly reviewing these updates can provide context on trial outcomes, regulatory designations, and Vistagen’s stated plans for its late-stage programs in mental health and women’s health.
Vistagen (VTGN) has been granted a U.S. patent for AV-101, its oral non-opioid product candidate for treating neuropathic pain. The patent extends until at least 2034 and is part of Vistagen's global patent portfolio for AV-101's manufacturing methods and therapeutic uses involving the NMDA receptor.
Preclinical studies published in The Journal of Pain showed AV-101's antinociceptive effects similar to gabapentin but with a better side effect profile. Additional research comparing AV-101 to pregabalin demonstrated significant dose response and similar efficacy in chronic neuropathic pain models.
Clinical data from Phase 1 studies published in the Scandinavian Journal of Pain indicated that oral AV-101 was well-tolerated, showing no meaningful difference in adverse events between AV-101 and placebo. The company is now seeking strategic collaborations to advance AV-101's clinical development and commercialization for pain and dyskinesias.
Vistagen (VTGN) announced positive results from an exploratory Phase 2A study of PH284, a pherine nasal spray designed to treat cancer cachexia. The double-blind, placebo-controlled study involved 40 female patients with terminal cancer-induced cachexia. PH284 demonstrated significant improvements in subjective feelings of hunger (SFH), with patients reporting a 71% improvement versus baseline prior to dinner on Day 7, compared to less than 1% in the placebo group.
The treatment protocol involved administering PH284 nasal spray (0.4 µg/50 µL) four times daily before meals. The study showed cumulative positive effects on hunger scores throughout the treatment period. Safety results were favorable, with no serious adverse events reported and an adverse event profile similar to placebo. PH284 becomes the fifth pherine product candidate in Vistagen's neuroscience pipeline to show positive efficacy signals.
Vistagen (VTGN) has initiated a repeat dose study for fasedienol, its investigational nasal spray for treating Social Anxiety Disorder (SAD). The exploratory Phase 2 trial will evaluate the efficacy, safety, and tolerability of repeat doses in adults with SAD during public speaking challenges.
The multi-center, randomized, double-blind, placebo-controlled study includes three arms: fasedienol followed by fasedienol (6.4 micrograms total), fasedienol followed by placebo (3.2 micrograms total), and placebo followed by placebo. The second dose will be administered ten minutes after the initial dose. The study design mirrors the ongoing PALISADE Phase 3 studies, including an open-label extension.
Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience company, announced its participation in the Stifel 2024 Healthcare Conference in New York City on November 18-19, 2024. CEO Shawn Singh will lead a fireside chat on November 18 at 3:35 p.m. Eastern Time. The presentation will be available via webcast on the company's website through the 'Events' page in the 'Investors' section. Interested investors can arrange one-on-one meetings through their Stifel representatives.
Vistagen (VTGN) reported financial results for Q2 FY2025 ended September 30, 2024. The company initiated PALISADE-4 Phase 3 trial for fasedienol in social anxiety disorder treatment, with both PALISADE-3 and PALISADE-4 trials progressing towards top-line results in 2025. Net loss increased to $13.0 million compared to $6.6 million in the same quarter last year. R&D expenses rose to $10.2 million from $3.9 million, while G&A expenses increased to $4.2 million from $3.2 million. The company maintained a strong cash position of $97.6 million as of September 30, 2024.
Vistagen (Nasdaq: VTGN) announced its participation in the 2024 Neuroscience Education Institute Congress in Colorado Springs, presenting three key posters on November 8, 2024. The presentations will showcase new prevalence data for social anxiety disorder (SAD) related to fasedienol, their lead intranasal pherine product in Phase 3 development. Additional presentations will cover itruvone, their Phase 2 candidate for major depressive disorder, and PH80, a hormone-free treatment in Phase 2 development for menopausal hot flashes.
The posters will address SAD prevalence trends, itruvone's effects on nasal receptors and olfactory bulb electrograms, and pain symptom analysis for PH80 in PMDD treatment. All presentations are scheduled for 3:35 p.m. Mountain Time, with posters becoming available on Vistagen's website on November 11, 2024.
Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience company, will host a conference call and webcast on November 7, 2024, at 2:00 p.m. Pacific Time to report its fiscal year 2025 second quarter results ended September 30, 2024, and provide a corporate update. The call will be accessible via toll-free and international dial-in numbers, with a webcast option available. A replay will be accessible after the call using provided replay access numbers.
Vistagen, The Goldie Hawn Foundation, and MindUP students will ring the Nasdaq Closing Bell on October 10, 2024, in honor of World Mental Health Day and The Goldie Hawn Foundation's 20th Anniversary. This event brings together Vistagen CEO Shawn Singh, Foundation Founder Goldie Hawn, and MindUP students to raise awareness about the roles of mindfulness and neuroscience in mental health.
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company focusing on neuroscience-based therapies for psychiatric disorders. MindUP is a neuroscience-based preventative mental health program for youth. The joint ceremony highlights their shared commitment to advancing neuroscience-based innovation and improving mental well-being.
Goldie Hawn emphasized the importance of understanding brain function for mental fitness and resilience in children. Shawn Singh highlighted Vistagen's belief in a multifaceted approach to improving mental health through awareness, education, and improved patient care.
Vistagen (Nasdaq: VTGN) has initiated the PALISADE-4 Phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray for the acute treatment of social anxiety disorder (SAD). This marks a significant milestone in the company's registration-directed PALISADE Phase 3 program. Fasedienol is designed for non-systemic, rapid activation of nose-to-brain neural circuits to reduce fear and anxiety associated with SAD.
CEO Shawn Singh highlighted the potential of fasedienol to provide a transformative acute treatment option for over 30 million Americans suffering from SAD, which is associated with increased risk for depression, alcohol abuse, and suicide attempts. Notably, current FDA-approved pharmacological therapies do not include an acute treatment option for SAD.
Vistagen (Nasdaq: VTGN) reported financial results for Q1 FY2025 and provided a corporate update. Key highlights include:
1. PALISADE Phase 3 Program for fasedienol in Social Anxiety Disorder (SAD) is progressing on track.
2. R&D expenses increased to $7.6 million, up from $4.2 million in Q1 FY2024.
3. G&A expenses rose to $4.6 million, compared to $3.0 million in Q1 FY2024.
4. Net loss widened to $10.7 million, versus $6.9 million in Q1 FY2024.
5. Cash, cash equivalents, and marketable securities stood at $108.4 million as of June 30, 2024.
6. The company is also advancing itruvone for Major Depressive Disorder and PH80 for menopausal hot flashes.